Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 1:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Influenza Immunity Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su, Flu D-QIV, mRNA-1273
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
46
States / cities
Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Influenza Vaccination in Bone Marrow Transplantation

NCT00419224
View directory record Official record
Conditions
Influenza
Interventions
inactivated split-virus influenza vaccine
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 10, 2007 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Phase 1 Interventional

VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old

NCT00973895
View directory record Official record
Conditions
Influenza A Virus, H1N1 Subtype, Novel Swine-Origin
Interventions
VRC-FLUDNA057-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Not applicable Interventional Results available

Open-Label Influenza Vaccine Evaluation

NCT02872311
View directory record Official record
Conditions
Immune Response
Interventions
High Dose Influenza vaccine, Adjuvanted Influenza vaccine, Standard Dose Influenza vaccine, Recombinant Influenza vaccine
Biological
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
65 Years to 74 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly

NCT01232868
View directory record Official record
Conditions
Influenza
Interventions
trivalent Influenza vaccine (TIV)
Biological
Lead sponsor
Emory University
Other
Eligibility
25 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2015 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Phase 4 Interventional

Randomized Influenza Vaccine Evaluation of Immune Response

NCT03598439
View directory record Official record
Conditions
Influenza
Interventions
Standard IIV4, Recombinant, Cell-culture
Biological
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Phase 1 Interventional

VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...

NCT00858611
View directory record Official record
Conditions
Influenza, Human
Interventions
VRC-FLUDNA047-00-VP, Flulaval (Registered) Seasonal Influenza Vaccine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine

NCT00722774
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H2N2 1960 AA ca recombinant vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2008 · Synced Sep 17, 2026, 1:00 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults

NCT06863142
View directory record Official record
Conditions
Influenza Prevention, Seasonal Influenza
Interventions
VRC-FLUMOS0116-00-VP, ALFQ
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Phase 4 Interventional Results available

Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents

NCT02250274
View directory record Official record
Conditions
Immune Response to Influenza Vaccine, Influenza A Virus Infection, Influenza B Virus Infection
Interventions
LAIV, IIV
Biological
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
5 Years to 17 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 17, 2026, 1:00 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

NK Cell Mediated Influenza Immunity During Pregnancy

NCT03196245
View directory record Official record
Conditions
Pregnancy Related, Influenza, Human
Interventions
There is no intervention.
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

NCT00835926
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

NCT03028974
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 49 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 17, 2026, 1:00 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

NCT05108818
View directory record Official record
Conditions
Influenza, Human
Interventions
Seasonal influenza vaccine
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over

NCT00232947
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (Fluviral), Influenza virus vaccine (Fluzone)
Biological
Lead sponsor
ID Biomedical Corporation, Quebec
Industry
Eligibility
50 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Pembroke Pines, Florida • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2007 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

NCT02814643
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Benralizumab Placebo, Seasonal influenza virus vaccine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 21 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Mesa, Arizona • Huntington Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Phase 2 Interventional Results available

A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo

NCT01359150
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
51
States / cities
Gilbert, Arizona • Paradise Valley, Arizona • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Phase 1 Interventional

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults

NCT05968989
View directory record Official record
Conditions
Influenza
Interventions
VRC-FLUMOS0116-00-VP( FLUMos-v2)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 17, 2026, 1:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Immune Response After Vaccination in Multiple Myeloma Patients

NCT02294487
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunologic Response to FluMist vs. Flucelvax

NCT03982069
View directory record Official record
Conditions
Influenza, Human, Immune Response
Interventions
FluMist live attenuated influenza vaccine, Flucelvax inactivated influenza vaccine
Biological
Lead sponsor
Richard Zimmerman MD
Other
Eligibility
4 Years to 21 Years
Enrollment
465 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 17, 2026, 1:00 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children

NCT01097941
View directory record Official record
Conditions
2009 H1N1 Influenza
Interventions
Live Attenuated H1N1 Influenza Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live
Biological
Lead sponsor
University of Rochester
Other
Eligibility
4 Years to 9 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot

NCT01518478
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluzone® Intradermal (Sanofi Pasteur Inc.)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 17, 2026, 1:00 PM EDT
Completed No phase listed Observational

Ovarian Cancer and Immune Response to Flu Vaccine

NCT00478387
View directory record Official record
Conditions
Ovarian Cancer
Interventions
The current season's trivalent killed influenza vaccine
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Sep 17, 2026, 1:00 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine

NCT03748524
View directory record Official record
Conditions
Immunity, Cellular
Interventions
Influenza Vaccine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 17, 2026, 1:00 PM EDT